Mereo BioPharma Group press release (NASDAQ:MREO): Q3 GAAP EPS of -$0.02 in-line.
The company reported cash and cash equivalents of $80.5 million as of September 30, 2024, which the company believes will provide runway into 2027, through multiple key inflection points.